tetano
Editor, Senior Moderator
Virus Res. 2015 Jan 16. pii: S0168-1702(15)00013-1. doi: 10.1016/j.virusres.2015.01.007. [Epub ahead of print]
[h=1]H5N1 Influenza Virus-Like Particle Vaccine Protects Mice from Heterologous Virus Challenge better than Whole Inactivated Virus.[/h] Ren Z[SUP]1[/SUP], Ji X[SUP]2[/SUP], Meng L[SUP]3[/SUP], Wei Y[SUP]4[/SUP], Wang T[SUP]5[/SUP], Feng N[SUP]5[/SUP], Zheng X[SUP]5[/SUP], Wang H[SUP]5[/SUP], Li N[SUP]5[/SUP], Gao X[SUP]5[/SUP], Jin H[SUP]6[/SUP], Zhao Y[SUP]5[/SUP], Yang S[SUP]5[/SUP], Qin C[SUP]7[/SUP], Gao Y[SUP]8[/SUP], Xia X[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The highly pathogenic avian influenza (HPAI) H5N1 virus has become highly enzootic since 2003 and has dynamically evolved to undergo substantial evolution. Clades 2.3.2.1 and 2.3.4 have become the most dominant lineage in recent years, and H5N8 avian influenza outbreaks have been reported Asia. The current approach to generate influenza virus vaccines uses embryonated chicken eggs for large-scale production, although such vaccines have been poorly immunogenic to heterologous virus challenge. In the current study, virus-like particles (VLP) based on A/meerkat/Shanghai/SH-1/2012 (clade 2.3.2.1) and comprising hemagglutinin (HA), neuraminidase (NA), and matrix (M1) were produced using a baculovirus expression system to develop effective protection for different H5 HPAI clade challenges. Mice immunized with VLP demonstrated stronger humoral and cellular immune responses than mice immunized with whole influenza virus (WIV), with 20-fold higher IgG antibody titers against A/meerkat/Shanghai/SH-1/2012 after boost. Notably, the WIV vaccine group showed partial protection (80% survival) to homologous challenge, little protection (40% survival) to heterologous challenge, and 20% survival to H5N8 challenge, whereas all mice in the VLP+CFA group survived. These results provide insight for the development of effective prophylactic vaccines based on VLPs with cross-clade protection for the control of current H5 HPAI outbreaks in humans.
Copyright ? 2015. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] H5N1 influenza; cross-protective; protection; vaccine; virus-like particles
PMID: 25599603 [PubMed - as supplied by publisher]
[h=1]H5N1 Influenza Virus-Like Particle Vaccine Protects Mice from Heterologous Virus Challenge better than Whole Inactivated Virus.[/h] Ren Z[SUP]1[/SUP], Ji X[SUP]2[/SUP], Meng L[SUP]3[/SUP], Wei Y[SUP]4[/SUP], Wang T[SUP]5[/SUP], Feng N[SUP]5[/SUP], Zheng X[SUP]5[/SUP], Wang H[SUP]5[/SUP], Li N[SUP]5[/SUP], Gao X[SUP]5[/SUP], Jin H[SUP]6[/SUP], Zhao Y[SUP]5[/SUP], Yang S[SUP]5[/SUP], Qin C[SUP]7[/SUP], Gao Y[SUP]8[/SUP], Xia X[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The highly pathogenic avian influenza (HPAI) H5N1 virus has become highly enzootic since 2003 and has dynamically evolved to undergo substantial evolution. Clades 2.3.2.1 and 2.3.4 have become the most dominant lineage in recent years, and H5N8 avian influenza outbreaks have been reported Asia. The current approach to generate influenza virus vaccines uses embryonated chicken eggs for large-scale production, although such vaccines have been poorly immunogenic to heterologous virus challenge. In the current study, virus-like particles (VLP) based on A/meerkat/Shanghai/SH-1/2012 (clade 2.3.2.1) and comprising hemagglutinin (HA), neuraminidase (NA), and matrix (M1) were produced using a baculovirus expression system to develop effective protection for different H5 HPAI clade challenges. Mice immunized with VLP demonstrated stronger humoral and cellular immune responses than mice immunized with whole influenza virus (WIV), with 20-fold higher IgG antibody titers against A/meerkat/Shanghai/SH-1/2012 after boost. Notably, the WIV vaccine group showed partial protection (80% survival) to homologous challenge, little protection (40% survival) to heterologous challenge, and 20% survival to H5N8 challenge, whereas all mice in the VLP+CFA group survived. These results provide insight for the development of effective prophylactic vaccines based on VLPs with cross-clade protection for the control of current H5 HPAI outbreaks in humans.
Copyright ? 2015. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] H5N1 influenza; cross-protective; protection; vaccine; virus-like particles
PMID: 25599603 [PubMed - as supplied by publisher]